Macular Function During Anti-VEGF Treatment

NCT ID: NCT01023971

Last Updated: 2009-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the changes in macular function during anti-VEGF treatment for neovascular age-related macular degeneration.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Macular function will be investigated using visual acuity, contrast sensitivity, mfERG and microperimetry.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Age Related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Patients investigated with mfERG and MP-1

No interventions assigned to this group

Group B

Patients investigated by Laser Doppler Flowmetry

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Neovascular AMD in first or second eyes
* angiographic signs of active subfoveal or juxtafoveal choroidal neovascularization (CNV)
* BCVA ≥35 ETDRS letters

Exclusion Criteria

* Spherical equivalent ≥ ± 6 D
* Previous treatments for CNV in the studied eye
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Royal Liverpool University Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Royal Liverpool University Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Simon P HARDING, FRCOphth, MD

Role: PRINCIPAL_INVESTIGATOR

University of Liverpool

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Eye Research Centre

Liverpool, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Simon P Harding, FRCOphth, MD

Role: CONTACT

Phone: +44 0151 706

Email: [email protected]

Claudio S Campa, MD, PhD

Role: CONTACT

Phone: +44 0151 706

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Simon P HARDING, FRCOphth, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Campa C, Hagan R, Sahni JN, Brown MC, Beare NA, Heimann H, Harding SP. Early multifocal electroretinogram findings during intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3446-51. doi: 10.1167/iovs.10-6588.

Reference Type DERIVED
PMID: 21357390 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Trust R&D_3704

Identifier Type: -

Identifier Source: org_study_id